Neurofilaments, Nerve-muscle Test Reflect SMA Severity in Very Young

Neurofilaments, Nerve-muscle Test Reflect SMA Severity in Very Young

311617

Neurofilaments, Nerve-muscle Test Reflect SMA Severity in Very Young

The blood levels of neurofilaments — a marker of nerve cell damage — and the results of a nerve-muscle test called compound muscle action potential (CMAP) may serve as a biomarker of disease onset and treatment response in infants and children with spinal muscular atrophy (SMA) up to 3 years old, a study suggests. In addition, in infants with SMA type 1, the therapy Zolgensma was unexpectedly associated with a temporary rise in neurofilament levels that was…

You must be logged in to read/download the full post.